US EditionPublished • loading... • Updated
Warning of 'Gastrointestinal Adverse Events' in Children Taking Weight-Loss Jabs
Studies involving 1,402 children show GLP-1 agonists significantly improve weight and blood sugar control in obese youths despite increased gastrointestinal side effects.
- Researchers suggest weight-loss injections like GLP-1 agonists could help children aged six to 17 with obesity or type 2 diabetes.
- Recent NHS data reveals that 22.1% of Year 6 students were classified as obese during 2023/24, marking a slight decrease from 22.7% the previous year.
- A meta-analysis of 18 trials involving 1,402 children showed these drugs significantly improved weight and blood sugar control but increased gastrointestinal side effects.
- Researchers emphasized the need for extended follow-up periods and additional practical studies to better determine the long-term impact of GLP-1 receptor agonists on children.
- NHS prescriptions have strict criteria requiring in-person checks, and while these drugs are approved only for adults, their broader use in children depends on further evidence.
Insights by Ground AI
13 Articles
13 Articles
Daily PostReposted by 
Wales Online
Wales OnlineWeight-loss jabs could be given to children as young as six
Researchers found the drugs “significantly improved” the likes of glycaemic control and weight in obese children
·Colwyn Bay, United Kingdom
Read Full Article
Coverage Details
Total News Sources13
Leaning Left6Leaning Right0Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 46%
C 54%
Factuality
To view factuality data please Upgrade to Premium
